Blood-Brain Barrier– tag –
-
Engineered Antibody Brainshuttle™ Technology Boosts Brain Drug Delivery of RNA-Based ASOs by Dual-Targeting TfR1 and CD98hc Receptors, Illuminating CNS Disease Treatment
EMJ Unknown Overview Antibody-based Brainshuttle™ technology has made significant strides in brain drug delivery for promising therapeutics like RNA-based antisense oligonucleotides (ASOs), which are otherwise unable to cross the blood-b... -
Focused Ultrasound BBB Opening Facilitates Limited LNP-modRNA Brain Delivery in Niemann-Pick Disease Type C Mouse Model but Fails to Induce Therapeutic Effect
bioRxiv Unknown Overview Efficient molecular therapeutic delivery to the central nervous system (CNS) remains a major barrier in neurogenetic disorders like Niemann-Pick Disease Type C (NPC). This preprint evaluated Focused ultrasound-me... -
Identifying Blood-Brain Barrier (BBB) Bottleneck: Nanomedicine Key to Overcoming Glioblastoma Brain Drug Delivery Challenges
Neuroscience News Unknown Overview The blood-brain barrier (BBB), a major obstacle to brain drug delivery, severely limits therapies for neurological disorders like glioblastoma. Recent research identified intracellular sorting after dru... -
Breaking the Blood-Brain Barrier: Next-Gen Strategies Unveil Neurological Drug Delivery Innovation
Pharmaceutical Conferences 2026 International会議 Overview A recent conference on June 22, 2026, showcased groundbreaking drug delivery strategies designed to circumvent the formidable blood-brain barrier (BBB). These innovations, includ... -
FDA Grants Accelerated Approval to AVLAYAH, a BBB-Penetrating Biologic, Ushering in a New Era for Brain Drug Delivery
Drug Delivery Leader USA Overview On March 25, 2026, the FDA granted accelerated approval to AVLAYAH (tividenofusp alfa-eknm), the first biologic engineered to traverse the blood-brain barrier (BBB). This landmark decision, following dec... -
Insilico Medicine Initiates Phase 1 Trial for AI-Designed Brain-Penetrant NLRP3 Inhibitor ISM8969 for Neuroinflammation
World Pharma Today Hong Kong Overview Insilico Medicine has completed dosing of the first patient in a Phase 1 trial for ISM8969, an AI-designed brain-penetrant NLRP3 inhibitor targeting neuroinflammatory and CNS diseases like Parkinson'... -
Neuron Reports Novel Small Molecule Temporarily Opens Blood-Brain Barrier, Significantly Enhancing CNS Drug Delivery Preclinically
Neuron USA Overview A research paper in Neuron presented compelling preclinical data for a novel small molecule designed to temporarily and reversibly open the blood-brain barrier (BBB). This groundbreaking technology holds the potential... -
Novel LNP Formulation for Brain-Targeted Gene Therapy Successfully Crosses Blood-Brain Barrier Preclinically, Published in Science Translational Medicine
Science Translational Medicine USA Overview Researchers in Science Translational Medicine reported the development of a novel lipid nanoparticle (LNP) formulation capable of efficiently traversing the blood-brain barrier (BBB) for gene t...
